Trade-Ideas LLC identified

PRA Health

(

PRAH

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified PRA Health as such a stock due to the following factors:

  • PRAH has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $14.6 million.
  • PRAH has traded 75,296 shares today.
  • PRAH is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PRAH with the Ticky from Trade-Ideas. See the FREE profile for PRAH NOW at Trade-Ideas

More details on PRAH:

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. PRAH has a PE ratio of 38. Currently there are 5 analysts that rate PRA Health a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for PRA Health has been 395,000 shares per day over the past 30 days. PRA Health has a market cap of $3.0 billion and is part of the health care sector and health services industry. Shares are up 9.3% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates PRA Health as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 3.9%. Since the same quarter one year prior, revenues rose by 15.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • PRA HEALTH SCIENCES INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, PRA HEALTH SCIENCES INC turned its bottom line around by earning $1.29 versus -$0.37 in the prior year. This year, the market expects an improvement in earnings ($2.37 versus $1.29).
  • When compared to other companies in the Life Sciences Tools & Services industry and the overall market, PRA HEALTH SCIENCES INC's return on equity is below that of both the industry average and the S&P 500.
  • The gross profit margin for PRA HEALTH SCIENCES INC is currently lower than what is desirable, coming in at 29.70%. Regardless of PRAH's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 6.64% trails the industry average.
  • The debt-to-equity ratio of 1.27 is relatively high when compared with the industry average, suggesting a need for better debt level management. Even though the debt-to-equity ratio is weak, PRAH's quick ratio is somewhat strong at 1.03, demonstrating the ability to handle short-term liquidity needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.